Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Trial of Ixabepilone and Carboplatin With or Without Bevacizumab in Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
Verified date | December 2021 |
Source | SCRI Development Innovations, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each cohort (Cohorts A and B).
Status | Completed |
Enrollment | 82 |
Est. completion date | September 2012 |
Est. primary completion date | September 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Histologically confirmed non-small-cell bronchogenic carcinoma (squamous carcinoma, adenocarcinoma, or large cell carcinoma). Cytologic specimens obtained by brushings, washings, or needle aspiration of the defined lesion are acceptable. Mixed tumors with small-cell anaplastic elements are not eligible. 2. Patients who have newly diagnosed unresectable stage III or IV disease are eligible. Patients with stage III disease should be ineligible for combined modality therapy 3. Patients must not have received any prior antineoplastic chemotherapy for metastatic lung cancer prior to study entry. 4. Patients who have had previous radiotherapy as definitive therapy for locally advanced non-small-cell are eligible as long as the recurrence is outside the original radiation port. Radiation therapy must have been completed greater than 4 weeks prior to registration. 5. Male or female patients >=18 years of age. 6. Life expectancy of at least 3 months. 7. ECOG performance status of <=1. 8. Measurable disease by RECIST criteria (see Section 7). 9. Laboratory values as follows: - ANC >=1500/mm3 (7 days prior to treatment); - Hemoglobin >=8 g/dL; - Platelets >=100,000 mm3 (7 days prior to treatment) - Bilirubin <=1 x ULN for institution - AST/SGOT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases and - ALT/SGPT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases - Creatinine <=2.0 mg/dL or - Calculated (measured) GFR >=40 mL/min - PT/INR and PTT <=1.5 x ULN 10. Peripheral neuropathy <= grade 1. Exclusion Criteria: 1. A history of cardiac disease as defined by malignant hypertension, unstable angina, congestive heart failure of > grade 2 per New York Heart Association (NYHA) criteria (see Appendix B), myocardial infarction within the previous 6 months, or symptomatic cardiac arrhythmias. 2. Metastatic brain or meningeal tumors. 3. Uncontrolled intercurrent illness. 4. Chemotherapy, investigational drug therapy, or major surgery = 4 weeks prior to starting study drug, or patients who have not recovered from side effects of previous therapy. 5. Patient is <=5 years free of another primary malignancy, except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Exclusion Criteria for Enrollment on Bevacizumab (Cohort B): 1. Patients with squamous cell histology NSCLC. 2. Patients who have had a major surgical procedure (not including mediastinoscopy), open biopsy, or significant traumatic injury within 1 month of beginning bevacizumab. 3. Patients who have had primary thoracic radiation within 3 months of beginning bevacizumab. 4. Fine needle aspiration, core biopsy, mediastinoscopy or other minor surgical procedure within 7 days of beginning bevacizumab. 5. Patients receiving thrombolytic therapy within 10 days of starting bevacizumab. 6. Patients with serious non-healing wound, ulcer, or bone fracture. 7. Patients with evidence of bleeding diathesis or coagulopathy. 8. Patients with history of hemoptysis (defined as bright red blood of ½ teaspoon or more per episode) within 3 months prior to study enrollment. 9. Patients with proteinuria at screening, as demonstrated by either: - Urine protein : creatinine (UPC) ratio >=1.0 or - Urine dipstick for protein >=2+ (patients discovered to have >=2+ proteinuria on dipstick at baseline should undergo a 24-hour urine collection, and must demonstrate <1 g of protein in 24 hours to be eligible). 10. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab. |
Country | Name | City | State |
---|---|---|---|
United States | Center for Cancer and Blood Disorders | Bethesda | Maryland |
United States | Oncology Hematology Care | Cincinnati | Ohio |
United States | South Carolina Oncology Associates | Columbia | South Carolina |
United States | Florida Cancer Specialists | Fort Myers | Florida |
United States | Gainsville Hematology Oncology Associates | Gainesville | Florida |
United States | Grand Rapids Clinical Oncology Program | Grand Rapids | Michigan |
United States | Dr. Donald Berdeaux | Great Falls | Montana |
United States | Research Medical Center | Kansas City | Missouri |
United States | Consultants in Blood Disorders and Cancer | Louisville | Kentucky |
United States | Tennessee Oncology, PLLC | Nashville | Tennessee |
United States | Peninsula Cancer Institute | Newport News | Virginia |
United States | Spartanburg Regional Medical Center | Spartanburg | South Carolina |
United States | Providence Medical Group | Terre Haute | Indiana |
Lead Sponsor | Collaborator |
---|---|
SCRI Development Innovations, LLC | Bristol-Myers Squibb, Genentech, Inc. |
United States,
Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment | The Percentage of Patients Who Experience an Objective Benefit From Treatment | 18 months | |
Secondary | Progression Free Survival, the Length of Time, That Patients Were Alive From Their First Date of Treatment Until Worsening of Their Disease | 18 months | ||
Secondary | Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death | 18 months | ||
Secondary | Number of Participants Experiencing Treatment Related Toxicity | Number of participants experiencing Grade 3 and Grade 4 Treatment-related toxicities are reported here. Toxicities that were occurring >=5% of total patients are listed. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE version 3.0) of the National Cancer Institute. | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |